U.S., July 4 -- ClinicalTrials.gov registry received information related to the study (NCT07050186) titled 'Cemiplimab for the Treatment of Incurable Metastatic or Unresectable NUT Carcinoma' on June 25.
Brief Summary: This phase II trial studies how well cemiplimab works in treating patients with nuclear protein of testis (NUT) carcinoma for which no treatment is currently available (incurable) and that has spread from where it first started (primary site) to other places in the body (metastatic) or cannot be removed by surgery (resectable). Immunotherapy with monoclonal antibodies, such as cemiplimab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Study Start Da...